ASCLS eNewsBytes

• Steady rise in US cases of tick-borne babesiosis disease October 15, 2024
  Rates of babesiosis increased an average 9% a year in the U.S. between 2015 and 2022, researchers reported in the journal Open Forum Infectious Diseases. Further, 4 in 10 patients with babesiosis also were infected with other tick-borne illnesses like Lyme disease, researchers said.
• UGA partners with FDA to test US dairy supplies for avian influenza October 15, 2024
  The University of Georgia is one of five institutions nationwide helping to ensure the safety of dairy products during the highly pathogenic Avian Influenza A outbreak to reduce the threat of avian influenza to human and animal health.
• Innovative blood test validated for comprehensive early Alzheimer's diagnosis October 15, 2024
  Scientists at the University of Pittsburgh have validated a new blood test platform capable of simultaneously measuring more than 100 biomarkers of Alzheimer's disease. This new diagnostic has the potential to alter the landscape of AD diagnostics by allowing physicians to better understand, in a single test, the complex nature of AD.
• New cell culture model sheds light on immune protein's role in infectious diseases October 15, 2024
  In a recent Nature study, AML cells were used along with other cell-based models and extensive human genetic studies to gain new insights about an immune-signaling protein called tumor necrosis factor and its role in tuberculosis.
• US FDA approves Pfizer's drug for rare bleeding disorder October 15, 2024
  Pfizer has received FDA approval for its once-a-week injection, Hympavzi, for treating hemophilia A or B, a rare bleeding disorder primarily affecting men. The drug is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in patients aged 12 and older.